We use cookies for a better user experience. Read our Privacy Policy

I Agree

Hospital Infection Therapeutics Market

Hospital Infection Therapeutics Market (Therapeutics - Anti-bacterial Drugs, Anti-fungal Drugs, Anti-viral Drugs; Infection - Hospital Acquired Pneumonia, Urinary Tract Infections, Gastrointestinal Disorders, Bloodstream Infections, Surgical Site Infections, Other Hospital Infections) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Hospital Infection Therapeutics Market - Snapshot

Hospital-acquired infections are a highly prevalent adverse events in the health care industry. Presence of unhygienic conditions in and around hospitals along with improper sterilization techniques applied in these settings augments the prevalence of hospital-acquired infections in the low and middle income countries. The global hospital infection therapeutics market is characterized by increase in incidence of infections of resistance bacteria. The market is witnessing gradual rise in research and development activities to develop novel antibiotics, which are supported by government policies. Hence, the global hospital infection therapeutics market was valued at US$ 14.4 Bn in 2017 and is projected to expand at a significant CAGR of 2.4% from 2018 to 2026.

hospital infection therapeutics

Increase in the geriatric population which is more prone to hospital-acquired infections, significant patient population in developing countries demanding proper treatment, and investments by public and private players for R&D on anti-infective drugs against resistant bacteria are the major factors driving the global hospital infection therapeutics market. However, surge in the incidence of treatment-emergent resistance, significant investment required due to high attrition rate in clinical trials, and changing reimbursement policies are resulting in limited pipeline drugs. This is likely to restrain the global hospital infection therapeutics market during the forecast period. Investment in R&D on non-antibiotic treatment options and partnerships for co-development and commercialization of anti-infective agents are expected to fuel the growth of the global hospital infection therapeutics market.

In terms of therapeutics, the global hospital infection therapeutics market has been classified into anti-bacterial drugs, anti-fungal drugs, anti-viral drugs, and others. The others segment comprises drug classes such as anti-parasitic drugs. The anti-bacterial drugs segment has been divided into cell wall synthesis inhibitors, protein synthesis inhibitors, and others. The cell wall synthesis inhibitors sub-segment comprises cephalosporins, carbapenems, vancomycin, and others. The protein synthesis inhibitors sub-segment comprises aminoglycosides, linezolid, tigecycline, and others. The anti-fungal drugs segment has been categorized into Caspofungin, Amphotericin B, and others. The others sub-segment includes Triazoles, fluconazole, voriconazole, and others. The anti-bacterial drugs segment is projected to dominate the market during the forecast period owing to an increase in initiatives such as the Global Action Plan on Antimicrobial Resistance by WHO and Drive AB by Innovative Medicines Initiative, and presence of key companies such as Merck & Co., Inc. and Pfizer, Inc. engaged in the manufacture of anti-bacterial drugs. These initiatives are aimed at increasing research and development activities to overcome drug resistance. The relatively stable growth rate of the segment is attributed to increase in antibiotic resistance of bacteria and limited pipeline drug candidates. The anti-viral drugs segment is anticipated to register above average growth rate owing to rise in the prevalence of severe bloodstream infections and increase in focus on research and development to overcome the risk of virus structural mutations. Based on infection, the market has been divided into hospital acquired pneumonia, urinary tract infections, gastrointestinal disorders, bloodstream infections, surgical site infections, and other hospital infections. The hospital acquired pneumonia segment is likely to dominate the market during the forecast period with above average growth rate, followed by surgical site infections, due to increase in incidence rate of respiratory infections among the geriatric population, comparatively above average cost of therapy, and prevalence of multidrug-resistant micro-organisms in ICU units.

In terms of region, the global hospital infection therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe accounted for major share of 39% of the global market in terms of revenue in 2017. North America was another major market for hospital infection therapeutics in 2017. Relatively high cost of treatment compared to that in emerging countries, developed health care infrastructure, and larger reimbursement coverage which provides assured investment return for new market entrants contribute to the significant share of the two regions. However, high growth rate of the pharmaceutical industry in India and China and investment by global investors in China for development of novel treatment approaches for hospital-acquired infections are expected to propel the hospital infection therapeutics market in Asia Pacific.

Major players operating in the global hospital infection therapeutics market include Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, AstraZeneca, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Allergan plc, Sanofi S.A., Gilead Sciences, Inc., Basilea Pharmaceutica Ltd., and Bristol-Myers Squibb Company.

The global hospital infection therapeutics market has been segmented as follows:

Therapeutics

  • Anti-bacterial Drugs
  • Anti-fungal Drugs
  • Anti-viral Drugs
  • Others

Infection

  • Hospital Acquired Pneumonia
  • Urinary Tract Infections
  • Gastrointestinal Disorders
  • Bloodstream Infections
  • Surgical Site Infections
  • Other Hospital Infections

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa
Hospital Infection Therapeutics Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hospital Infection Therapeutics Market

4. Market Overview
     4.1. Introduction
            4.1.1. Therapeutics Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Hospital Infection Therapeutics Market Analysis and Forecast, 2016–2026
            4.4.1. Market Revenue Projections (US$ Mn)
            4.4.2. Market Volume/Unit Shipments Projections
     4.5. Porter’s Five Force Analysis

5. Market Outlook
     5.1.Regulatory Scenario by Region/globally
     5.2.Pipeline Analysis
     5.3.Reimbursement Scenario by Region/globally
     5.4.Disease Prevalence & Incidence Rate globally with key countries
     5.5.Healthcare Industry Overview
     5.6.Value Chain Analysis

6. Global Hospital Infection Therapeutics Market Analysis and Forecast, by Therapeutics
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Market Forecast, by Therapeutics, 2016–2026
            6.3.1. Antibacterial Drugs
                     6.3.1.1. Cell Wall Synthesis Inhibitors
                     6.3.1.2. Protein Synthesis Inhibitors
                     6.3.1.3. Others
            6.3.2. Antifungal Drugs
                     6.3.2.1. Caspofungin
                     6.3.2.2. Amphotericin B
                     6.3.2.3. Others
            6.3.3. Antiviral Drugs
            6.3.4. Others
     6.4. Market Attractiveness, by Therapeutics

7. Global Hospital Infection Therapeutics Market Analysis and Forecasts, by Infection
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Market Forecast, by Infection, 2016–2026
            7.3.1. Hospital Acquired Pneumonia
            7.3.2. Urinary Tract Infections
            7.3.3. Gastrointestinal Disorders
            7.3.4. Bloodstream Infections
            7.3.5. Surgical Site Infections
            7.3.6. Other Hospital Infections
     7.4. Market Attractiveness, by Infection

8. Global Hospital Infection Therapeutics Market Analysis and Forecasts, by Region
     8.1. Key Findings
     8.2. Market Forecast, by Region
            8.2.1. North America
            8.2.2. Europe
            8.2.3. Asia Pacific
            8.2.4. Latin America
            8.2.5. Middle East & Africa
     8.3. Market Attractiveness, by Country/Region

9. North America Hospital Infection Therapeutics Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
     9.2. Market Forecast, by Therapeutics, 2016–2026
            9.2.1. Antibacterial Drugs
                     9.2.1.1. Cell Wall Synthesis Inhibitors
                     9.2.1.2. Protein Synthesis Inhibitors
                     9.2.1.3. Others
            9.2.2. Antifungal Drugs
                     9.2.2.1. Caspofungin
                     9.2.2.2. Amphotericin B
                     9.2.2.3. Others
            9.2.3. Antiviral Drugs
            9.2.4. Others
     9.3. Market Forecast, by Infection, 2016–2026
            9.3.1. Hospital Acquired Pneumonia
            9.3.2. Urinary Tract Infections
            9.3.3. Gastrointestinal Disorders
            9.3.4. Bloodstream Infections
            9.3.5. Surgical Site Infections
            9.3.6. Other Hospital Infections
     9.4. Market Forecast, by Country, 2016–2026
            9.4.1. U.S.
            9.4.2. Canada
     9.5. Market Attractiveness Analysis
            9.5.1. By Therapeutics
            9.5.2. By Infection
            9.5.3. By Country

10. Europe Hospital Infection Therapeutics Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
     10.2. Market Forecast, by Therapeutics, 2016–2026
            10.2.1. Antibacterial Drugs
                     10.2.1.1. Cell Wall Synthesis Inhibitors
                     10.2.1.2. Protein Synthesis Inhibitors
                     10.2.1.3. Others
            10.2.2. Antifungal Drugs
                     10.2.2.1. Caspofungin
                     10.2.2.2. Amphotericin B
                     10.2.2.3. Others
            10.2.3. Antiviral Drugs
            10.2.4. Others
     10.3. Market Forecast, by Infection, 2016–2026
            10.3.1. Hospital Acquired Pneumonia
            10.3.2. Urinary Tract Infections
            10.3.3. Gastrointestinal Disorders
            10.3.4. Bloodstream Infections
            10.3.5. Surgical Site Infections
            10.3.6. Other Hospital Infections
     10.4. Market Forecast, by Country/Sub-region, 2016–2026
            10.4.1. Germany
            10.4.2. U.K.
            10.4.3. France
            10.4.4. Spain
            10.4.5. Italy
            10.4.6. Russia
            10.4.7. Rest of Europe
     10.5. Market Attractiveness Analysis
            10.5.1. By Therapeutics
            10.5.2. By Infection
            10.5.3. By Country/Sub-region

11. Asia Pacific Hospital Infection Therapeutics Market Analysis and Forecast
     11.1.Introduction
            11.1.1. Key Findings
     11.2.Market Forecast, by Therapeutics, 2016–2026
            11.2.1. Antibacterial Drugs
                     11.2.1.1. Cell Wall Synthesis Inhibitors
                     11.2.1.2. Protein Synthesis Inhibitors
                     11.2.1.3. Others
            11.2.2. Antifungal Drugs
                     11.2.2.1. Caspofungin
                     11.2.2.2. Amphotericin B
                     11.2.2.3. Others
            11.2.3. Antiviral Drugs
            11.2.4. Others
     11.3.Market Forecast, by Infection, 2016–2026
            11.3.1. Hospital Acquired Pneumonia
            11.3.2. Urinary Tract Infections
            11.3.3. Gastrointestinal Disorders
            11.3.4. Bloodstream Infections
            11.3.5. Surgical Site Infections
            11.3.6. Other Hospital Infections
     11.4.Market Forecast, by Country/Sub-region, 2016–2026
            11.4.1. China
            11.4.2. Japan
            11.4.3. India
            11.4.4. Australia & New Zealand
            11.4.5. Rest of Asia Pacific
     11.5.Market Attractiveness Analysis
            11.5.1. By Therapeutics
            11.5.2. By Infection
            11.5.3. By Country/Sub-region

12. Latin America Hospital Infection Therapeutics Market Analysis and Forecast
     12.1.Introduction
            12.1.1. Key Findings
     12.2.Market Forecast, by Therapeutics, 2016–2026
            12.2.1. Antibacterial Drugs
                     12.2.1.1. Cell Wall Synthesis Inhibitors
                     12.2.1.2. Protein Synthesis Inhibitors
                     12.2.1.3. Others
            12.2.2. Antifungal Drugs
                     12.2.2.1. Caspofungin
                     12.2.2.2. Amphotericin B
                     12.2.2.3. Others
            12.2.3. Antiviral Drugs
            12.2.4. Others
     12.3.Market Forecast, by Infection, 2016–2026
            12.3.1. Hospital Acquired Pneumonia
            12.3.2. Urinary Tract Infections
            12.3.3. Gastrointestinal Disorders
            12.3.4. Bloodstream Infections
            12.3.5. Surgical Site Infections
            12.3.6. Other Hospital Infections
     12.4.Market Forecast, by Country/Sub-region, 2016–2026
            12.4.1. Brazil
            12.4.2. Mexico
            12.4.3. Rest of Latin America
     12.5.Market Attractiveness Analysis
            12.5.1. By Therapeutics
            12.5.2. By Infection
            12.5.3. By Country/Sub-region

13. Middle East & Africa Hospital Infection Therapeutics Market Analysis and Forecast
     13.1.Introduction
            13.1.1. Key Findings
     13.2.Market Forecast, by Therapeutics, 2016–2026
            13.2.1. Antibacterial Drugs
                     13.2.1.1. Cell Wall Synthesis Inhibitors
                     13.2.1.2. Protein Synthesis Inhibitors
                     13.2.1.3. Others
            13.2.2. Antifungal Drugs
                     13.2.2.1. Caspofungin
                     13.2.2.2. Amphotericin B
                     13.2.2.3. Others
            13.2.3. Antiviral Drugs
            13.2.4. Others
     13.3.Market Forecast, by Infection, 2016–2026
            13.3.1. Hospital Acquired Pneumonia
            13.3.2. Urinary Tract Infections
            13.3.3. Gastrointestinal Disorders
            13.3.4. Bloodstream Infections
            13.3.5. Surgical Site Infections
            13.3.6. Other Hospital Infections
     13.4.Market Forecast, by Country/Sub-region, 2016–2026
            13.4.1. GCC Countries
            13.4.2. South Africa
            13.4.3. Israel
            13.4.4. Rest of Middle East & Africa
     13.5.Market Attractiveness Analysis
            13.5.1. By Therapeutics
            13.5.2. By Infection
            13.5.3. By Country/Sub-region

14. Competition Landscape
     14.1.Market Player – Competition Matrix (By Tier and Size of companies)
     14.2.Market Share Analysis By Company (2017)
     14.3.Market Footprint Analysis
     14.4. Competitive Business Strategies
     14.5. Company Profiles
            14.5.1. Allergan
                     14.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.1.2. Product Portfolio
                     14.5.1.3. SWOT Analysis
                     14.5.1.4. Strategic Overview
                     14.5.1.5. Financial Overview
            14.5.2. AstraZeneca
                     14.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.2.2. Product Portfolio
                     14.5.2.3. SWOT Analysis
                     14.5.2.4. Strategic Overview
                     14.5.2.5. Financial Overview
            14.5.3. Basilea Pharmaceutica Ltd.
                     14.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.3.2. Product Portfolio
                     14.5.3.3. SWOT Analysis
                     14.5.3.4. Strategic Overview
                     14.5.3.5. Financial Overview
            14.5.4. Bayer AG
                     14.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.4.2. Product Portfolio
                     14.5.4.3. SWOT Analysis
                     14.5.4.4. Strategic Overview
                     14.5.4.5. Financial Overview
            14.5.5. Bristol-Myers Squibb Company
                     14.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.5.2. Product Portfolio
                     14.5.5.3. SWOT Analysis
                     14.5.5.4. Strategic Overview
                     14.5.5.5. Financial Overview
            14.5.6. F. Hoffman-La Roche Ltd.
                     14.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.6.2. Product Portfolio
                     14.5.6.3. SWOT Analysis
                     14.5.6.4. Strategic Overview
                     14.5.6.5. Financial Overview
            14.5.7. GlaxoSmithKline plc.
                     14.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.7.2. Product Portfolio
                     14.5.7.3. SWOT Analysis
                     14.5.7.4. Strategic Overview
                     14.5.7.5. Financial Overview
            14.5.8. Johnson & Johnson Services, Inc.
                     14.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.8.2. Product Portfolio
                     14.5.8.3. SWOT Analysis
                     14.5.8.4. Strategic Overview
                     14.5.8.5. Financial Overview
            14.5.9. Merck & Co., Inc.
                     14.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.9.2. Product Portfolio
                     14.5.9.3. SWOT Analysis
                     14.5.9.4. Strategic Overview
                     14.5.9.5. Financial Overview
            14.5.10. Pfizer Inc.
                     14.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.10.2. Product Portfolio
                     14.5.10.3. SWOT Analysis
                     14.5.10.4. Strategic Overview
                     14.5.10.5. Financial Overview
            14.5.11. Sanofi
                     14.5.11.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.11.2. Product Portfolio
                     14.5.11.3. SWOT Analysis
                     14.5.11.4. Strategic Overview
                     14.5.11.5. Financial Overview

List of Tables

Table 01 WHO priority list and drug candidates in pre-clinical and clinical development
Table 02 Pipeline Analysis of Hospital Infection Therapeutics (1/5)
Table 03 Pipeline Analysis of Hospital Infection Therapeutics (2/5)
Table 04 Pipeline Analysis of Hospital Infection Therapeutics (3/5)
Table 05 Pipeline Analysis of Hospital Infection Therapeutics (4/5)
Table 06 Pipeline Analysis of Hospital Infection Therapeutics (5/5)
Table 07 Disease Prevalence & Incidence Rate Globally, by Key Countries
Table 08 Healthcare Industry Overview
Table 09 Incidence Rate (per 100,000 population) of S. aureus bacteremia, U.K., 2013 (1/2)
Table 10 Table: Incidence Rate (per 100,000 population) of S. aureus bacteremia, U.K., 2013 (2/2)
Table 11 Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 12 Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-bacterial Drugs, 2016–2026
Table 13 Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-fungal Drugs, 2016–2026
Table 14 Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2016–2026
Table 15 Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 16 North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 17 North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 18 North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-bacterial Drugs, 2016–2026
Table 19 North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-fungal Drugs, 2016–2026
Table 20 North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2016–2026
Table 21 Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22 Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 23 Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-bacterial Drugs, 2016–2026
Table 24 Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-fungal Drugs, 2016–2026
Table 25 Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2016–2026
Table 26 Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 27 Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 28 Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-bacterial Drugs, 2016–2026
Table 29 Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-fungal Drugs, 2016–2026
Table 30 Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2016–2026
Table 31 Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 32 Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 33 Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics: Anti-bacterial Drugs, 2016–2026
Table 34 Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics: Anti-fungal Drugs, 2016–2026
Table 35 Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2016–2026
Table 36 Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 37 Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 38 Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Anti-bacterial Drugs, 2016–2026
Table 39 Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Anti-fungal Drugs, 2016–2026
Table 40 Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2016–2026

List of Figures

 

Figure 01 Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 02 Global Hospital Infection Therapeutics Market Value Share (%), by Therapeutics (2017)
Figure 03 Global Hospital Infection Therapeutics Market Value Share (%), by Region (2017)
Figure 04 Global Hospital Infection Therapeutics Market Value Share (%), by Infection (2017)
Figure 05 Percentage Distribution of Population Aged 65 and Over, by Region: 2015
Figure 06 Percentage Distribution of Population Aged 65 and Over, by Region: 2050
Figure 07 Regulatory Approval Process - U.S.
Figure 08 Regulatory Approval Process - Europe
Figure 09 Regulatory Approval Process - Japan
Figure 10 Global Hospital Infection Therapeutics Market Value Share (%), by Therapeutics, 2017 and 2026
Figure 11 Global Hospital Infection Therapeutics Market Attractiveness, by Therapeutics, 2018–2026
Figure 12 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anti-bacterial Drugs, 2016–2026
Figure 13 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anti-fungal Drugs, 2016–2026
Figure 14 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anti-viral Drugs, 2016–2026
Figure 15 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2016–2026
Figure 16 Global Hospital Infection Therapeutics Market Value Share (%), by Infection, 2017 and 2026
Figure 17 Global Hospital Infection Therapeutics Market Attractiveness, by Infection, 2018–2026
Figure 18 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Acquired Pneumonia, 2016–2026
Figure 19 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Urinary Tract Infections, 2016–2026
Figure 20 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Gastrointestinal Disorders, 2016–2026
Figure 21 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Bloodstream Infections, 2016–2026
Figure 22 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Surgical Site Infections, 2016–2026
Figure 23 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Other Hospital Infections, 2016–2026
Figure 24 Global Hospital Infection Therapeutics Market Value Share (%), by Region, 2017 and 2026
Figure 25 Global Hospital Infection Therapeutics Market Attractiveness, by Region, 2018–2026
Figure 26 North America Hospital Infection Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 27 North America Hospital Infection Therapeutics Market Value Share (%), by Country, 2017 and 2026
Figure 28 North America Hospital Infection Therapeutics Market Attractiveness, by Country, 2018–2026
Figure 29 North America Hospital Infection Therapeutics Market Value Share (%), by Therapeutics, 2017 and 2026
Figure 30 North America Hospital Infection Therapeutics Market Attractiveness, by Therapeutics, 2018–2026
Figure 31 North America Hospital Infection Therapeutics Market Value Share (%), by Infection, 2017 and 2026
Figure 32 North America Hospital Infection Therapeutics Market Attractiveness, by Infection, 2018–2026
Figure 33 Europe Hospital Infection Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 34 Europe Hospital Infection Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 35 Europe Hospital Infection Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 36 Europe Hospital Infection Therapeutics Market Value Share (%), by Therapeutics, 2017 and 2026
Figure 37 Europe Hospital Infection Therapeutics Market Attractiveness, by Therapeutics, 2018–2026
Figure 38 Europe Hospital Infection Therapeutics Market Value Share (%), by Infection, 2017 and 2026
Figure 39 Europe Hospital Infection Therapeutics Market Attractiveness, by Infection, 2018–2026
Figure 40 Asia Pacific Hospital Infection Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 41 Asia Pacific Hospital Infection Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 42 Asia Pacific Hospital Infection Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 43 Asia Pacific Hospital Infection Therapeutics Market Value Share (%), by Therapeutics, 2017 and 2026
Figure 44 Asia Pacific Hospital Infection Therapeutics Market Attractiveness, by Therapeutics, 2018–2026
Figure 45 Asia Pacific Hospital Infection Therapeutics Market Value Share (%), by Infection, 2017 and 2026
Figure 46 Asia Pacific Hospital Infection Therapeutics Market Attractiveness, by Infection, 2018–2026
Figure 47 Latin America Hospital Infection Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 48 Latin America Hospital Infection Therapeutics Market Value Share (%), by Country/Sub-region,
Figure 49 Latin America Hospital Infection Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 50 Latin America Hospital Infection Therapeutics Market Value Share (%), by Therapeutics, 2017 and 2026
Figure 51 Latin America Hospital Infection Therapeutics Market Attractiveness, by Therapeutics, 2018–2026
Figure 52 Latin America Hospital Infection Therapeutics Market Value Share (%), by Infection, 2017 and 2026
Figure 53 Latin America Hospital Infection Therapeutics Market Attractiveness, by Infection, 2018–2026
Figure 54 Middle East & Africa Hospital Infection Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 55 Middle East & Africa Hospital Infection Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 56 Middle East & Africa Hospital Infection Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 57 Middle East & Africa Hospital Infection Therapeutics Market Value Share (%), by Therapeutics, 2017 and 2026
Figure 58 Middle East & Africa Hospital Infection Therapeutics Market Attractiveness, by Therapeutics, 2018–2026
Figure 59 Middle East & Africa Hospital Infection Therapeutics Market Value Share (%), by Infection, 2017 and 2026
Figure 60 Middle East & Africa Hospital Infection Therapeutics Market Attractiveness, by Infection, 2018–2026
Figure 61 Global Hospital Infection Therapeutics Market Share, by Company, 2017
Figure 62 Competition Matrix (1/2)
Figure 63 Competition Matrix (2/2)

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

737

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved